Elevation Oncology Inc (NASDAQ: ELEV) is 2.83% higher on its value in year-to-date trading and has touched a low of $0.36 and a high of $5.83 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ELEV stock was last observed hovering at around $0.52 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $0.55, the stock is -0.28% and -14.60% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.91 million and changing 6.40% at the moment leaves the stock -79.40% off its SMA200. ELEV registered -17.96% loss for a year compared to 6-month loss of -86.66%. The firm has a 50-day simple moving average (SMA 50) of $0.65116 and a 200-day simple moving average (SMA200) of $2.680325.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -8.50% gain in the last 1 month and extending the period to 3 months gives it a -79.32%, and is 6.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.26% over the week and 7.64% over the month.
Elevation Oncology Inc (ELEV) has around 29 employees, a market worth around $32.64M and $0.00M in sales. Distance from 52-week low is 52.12% and -90.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.50%).
Elevation Oncology Inc quarterly earnings per share for the current quarter are estimated at -0.2.The EPS is expected to grow by 41.26% this year
106.0 institutions hold shares in Elevation Oncology Inc (ELEV), with institutional investors hold 100.06% of the company’s shares. The shares outstanding are 59.11M, and float is at 49.99M with Short Float at 12.30%. Institutions hold 99.82% of the Float.
The top institutional shareholder in the company is LOGOS GLOBAL MANAGEMENT LP with over 3.85 million shares valued at $10.39 million. The investor’s holdings represent 6.5234 of the ELEV Shares outstanding. As of 2024-06-30, the second largest holder is FARALLON CAPITAL MANAGEMENT LLC with 3.6 million shares valued at $9.72 million to account for 6.0971 of the shares outstanding. The other top investors are TANG CAPITAL MANAGEMENT LLC which holds 3.06 million shares representing 5.1848 and valued at over $8.26 million, while FRAZIER LIFE SCIENCES MANAGEMENT, L.P. holds 5.013 of the shares totaling 2.96 million with a market value of $7.99 million.
